The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.

Pre-exposure prophylaxis (PrEP) is a promising preventive tool in the fight against HIV [1], but it remains expensive. In 2010, a year's worth of tenofovir-emtricitabine (TDF-FTC, or Truvada, the sole drug approved for this regimen in the United States) cost $ 13 416 wholesale [2]. Insurance pol

[1]  D. Osmond,et al.  Recent decline in the incidence of human immunodeficiency virus infection among California men who have sex with men. , 2011, American journal of epidemiology.

[2]  R. B. Malgarini,et al.  Preexposure chemoprophylaxis for HIV prevention. , 2011, The New England journal of medicine.

[3]  K. Underhill.  Preexposure chemoprophylaxis for HIV prevention. , 2011, The New England journal of medicine.

[4]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[5]  Margaret L. Brandeau,et al.  The Cost-Effectiveness and Population Outcomes of Expanded HIV Screening and Antiretroviral Treatment in the United States , 2010, Annals of Internal Medicine.

[6]  R. Walensky.  Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[7]  R. Walensky,et al.  HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Weinstein.  How much are Americans willing to pay for a quality-adjusted life year? , 2008, Medical care.

[9]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[10]  Zhang Xing-quan.  Pre-exposure prophylaxis against HIV infection , 2011 .